Navigation Links
Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
Date:5/21/2008

CPF and ATS to Jointly Award $200,000 in research funding

TORONTO, May 21 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced the expansion of their research partnership in pulmonary fibrosis. CPF and ATS are making available two new two-year, $100,000 awards for researchers in the United States pursuing new approaches to understand and treat pulmonary fibrosis.

"We'd like to express our gratitude to ATS for continuing a clinical partnership that is desperately needed in the research community to make new funds available to investigators dedicated to improving our understanding of IPF," said Marvin Schwarz, MD, James C. Campbell Professor of Pulmonary Medicine, Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Denver and Chairman of the CPF Board of Directors.

ATS/CPF research awards are selected through a rigorous peer-review application process administered by ATS. Awards are selected from a series of applicants who submitted proposals in the areas of basic, clinical, genetic, and translational research that focus on identifying new approaches to understand or treating pulmonary fibrosis. The letter of intent deadline for the 2008 awards is 11:59 p.m. Eastern Time Wednesday, June 25, 2008 and the award recipients will be announced in December, 2008.

"We are proud to be able to match grants in this important area of research," said Thomas R. Martin, M.D., past president of ATS and Co-Chair of the ATS Research Program with Sharon Rounds. "The ATS continues its commitment to work with nationally recognized organizations like the CPF who are dedicated to advancing lung disease research."

The ATS/CPF Partnership Grant for Pulmonary Fibrosis was established in 2006. The first grant through this partnership was a $100,000, two-year award to Sonye K. Danoff, M.D., Ph.D. at Johns Hopkins University. Dr. Danoff is currently in year two of her research entitled "VEGF: Marker or mediator of lung injury in pulmonary fibrosis?" Her research is currently testing the hypothesis that locally elevated levels of vascular endothelial growth factor (VEGF) in the lungs of patients with autoimmune pulmonary fibrosis contribute to disease progression. In December, 2007, Andrew M. Tager, M.D. of Harvard Medical School and Massachusetts General Hospital was the recipient of a $100,000, two-year award to investigate the role of Lysophosphatidic Acid (LPA) and its cognate receptor LPA1 in lung injury and fibroproliferation following bleomycin treatment.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, which is the most prevalent of a classification of lung disorders known as interstitial lung diseases (ILD's). There is currently no known cause or cure for IPF, nor is there an FDA-approved treatment. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose, and an estimated two- thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 15,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.

About the American Thoracic Society

The American Thoracic Society (ATS) is a non-profit, international, professional and scientific society for respiratory, critical care and sleep medicine. The ATS is committed globally to the prevention and treatment of respiratory disease through research, education, patient care and advocacy. The long-range goal of the ATS is to decrease morbidity and mortality from respiratory disorders and life threatening acute illnesses in people of all ages. In keeping with these goals, the American Thoracic Society interacts with both national and international organizations which have similar goals. For more information please visit http://www.thoracic.org.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Joins the Personalized Medicine Coalition (PMC)
2. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
3. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
4. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
5. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
6. Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
7. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
8. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
9. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
10. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
11. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... /PRNewswire -- WuXi AppTec, a leading global pharmaceutical, ... platform, today announced that it has acquired HD ... discovery contract research organization (CRO). After completion of ... of WuXi, and will continue to focus on ... The acquisition will further strengthen WuXi,s R&D capability ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, Inc. ... enhancing productivity in aquaculture and a majority-owned subsidiary of ... it has completed the listing of its common shares ... subscription from Intrexon. "AquaBounty,s listing on NASDAQ ... broaden our exposure to the U.S. markets as we ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
Breaking Biology Technology:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
Breaking Biology News(10 mins):